Myores

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Myores

Quick Facts

Property Description
Active Ingredient Tizanidine Hydrochloride
Form Oral formulation (Tablet or Capsule)
Pharmacological Class Centrally Acting Skeletal Muscle Relaxant
Common Use Symptomatic relief of muscle spasticity and spasms
Origin Synthetic (Imidazoline derivative)

The Identity of Myores: A Centrally Acting Muscle Relaxant

Myores is a prescription-only synthetic pharmaceutical preparation whose active ingredient is Tizanidine Hydrochloride. It is classified as a Centrally Acting Skeletal Muscle Relaxant and an Antispastic Agent, used to manage conditions involving involuntary muscle stiffness. The active compound, Tizanidine, is an imidazoline derivative created via chemical synthesis. Tizanidine is categorized as a Central alpha-2 Adrenergic Agonist due to its specific mechanism of action.

Myores is designated a Centrally Acting Skeletal Muscle Relaxant because its mechanism specifically acts on the central nervous system—the brain and spinal cord—rather than directly on the muscle tissue itself. The agonistic action of Tizanidine on the alpha-2 receptors is associated with a reduction in the over-activity of motor neurons, which helps stabilize muscle tone.


General Purpose and Available Form

The primary general therapeutic purpose of Myores is to provide symptomatic relief from pathological muscle hypertonia and involuntary spasms known as spasticity, such as those that may stem from neurological conditions. Myores is presented as an oral formulation, available as a tablet or capsule. This administration route allows the Tizanidine Hydrochloride to be absorbed systemically, enabling its action on the central nerve pathways to promote sustained muscle relaxation.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Myores?

Possible Side Effects and Safety Information

The official safety profile for Myores (Tizanidine) classifies documented adverse reactions by frequency and physiological system, based on regulatory standards. The most frequently reported adverse reactions are generally related to its action on the central nervous system and vascular system.

Frequency Classification Examples of Documented Adverse Reactions
Very Common (ge 10%) Dry mouth, Somnolence (drowsiness), Asthenia (weakness/fatigue), Dizziness
Common (1-10%) Hypotension, Bradycardia, Tachycardia, Liver function test abnormalities, Urinary tract infection

Serious adverse reactions documented in regulatory sources include potential for clinically significant Hypotension, severe Hepatotoxicity (including Hepatitis and Hepatic failure), and life-threatening Hypersensitivity Reactions (such as Angioedema). These risks are explicitly highlighted in the official prescribing information.

Safety constraints require the drug to be contraindicated with potent CYP1A2 inhibitors (e.g., fluvoxamine or ciprofloxacin) due to the risk of severe, prolonged adverse effects. Furthermore, the official label notes that effects such as sedation may peak following initial titration, and abrupt discontinuation, particularly after prolonged high-dose use, may be associated with Rebound Hypertension.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section reflects the officially documented descriptions of overdose for Tizanidine Hydrochloride (Myores) as stated in government regulatory sources. Overdose requires immediate medical attention and contact with a Poison Help line, as mandated by regulatory labeling.

Overdose manifestations primarily affect the central nervous system (CNS) and the cardiovascular system. Documented clinical signs include profound CNS depression, which may present as somnolence, confusion, lethargy, and can progress to coma. Cardiovascular signs involve hypotension (low blood pressure) and bradycardia (slowed heart rate).

Severe outcomes officially listed in regulatory documents include circulatory collapse due to severe hypotension and the physiological finding of QT(c) prolongation, which carries a cardiac risk and requires electrocardiographic monitoring.

Regulators note that no specific antidote is known for Tizanidine overdose. Therefore, treatment must be symptomatic and supportive. Officially described supportive measures include ensuring an adequate airway, monitoring cardiovascular and respiratory systems, and procedural steps such as using gastric lavage or activated charcoal to remove unabsorbed drug. Patients with severe renal impairment are officially noted to be at increased risk, and signs like severe somnolence or dizziness in this population may be indicators of potential overdose.

Therapeutic Uses of Myores

What Myores Treats: Main Uses and Benefits

Myores (Tizanidine) is commonly applied in clinical settings that involve acute or unstable symptom patterns related to muscle spasticity resulting from neurological disorders. Tizanidine is relevant across therapeutic domains where additional symptomatic support is needed to address increased muscle tension.

Myores is commonly used across conditions where symptoms may intensify temporarily, such as Multiple Sclerosis (MS) and Spinal Cord Injury (SCI). This medication is relevant when symptoms cluster into patterns requiring supportive management, and is applied in addressing manifestations such as involuntary muscle spasms and clonus (repetitive, rhythmic movements). It is used for managing symptoms that interfere with daily comfort and contributes to easing the overall symptom load.

The medication is often used when symptoms intensify and supportive relief is needed, relevant in clinical scenarios such as supporting physical therapy or assisting with daily activities. Myores is utilized during difficult episodes to ease distress and contribute to improved comfort during periods of heightened symptoms.


Quick Fact: Support for Symptoms of Muscle Over-Activity

Property Description
Primary Target Symptom Spasticity and muscle hypertonia
Core Condition Categories Multiple Sclerosis, Spinal Cord Injury, Stroke
Symptom Benefit Easing involuntary spasms and stiffness
Functional Benefit Assists with maintaining functional stability

Regulatory References

  1. NIH DailyMed Label for Tizanidine

Eligibility and Restrictions for Use

Myores (Tizanidine) is approved for use in the adult population, defined as patients 18 years of age and older. Its use is established for managing spasticity related to neurological disorders such as Multiple Sclerosis and Spinal Cord Injury.


Populations Who Must Not Use (Contraindications)

Official regulatory labels specify that Myores is contraindicated and must not be used in patients with a known hypersensitivity to tizanidine or any component of its formulation. It is also strictly contraindicated for patients taking the strong CYP1A2 inhibitors Fluvoxamine or Ciprofloxacin.

Restricted and Non-Established Use

Population Group Regulatory Status Context of Restriction
Pediatric Patients Not Established Safety and efficacy have not been established in patients under 18 years of age.
Severe Hepatic Impairment Contraindicated / Avoid Use should ordinarily be avoided or used with extreme caution due to risk of liver injury.
Renal Impairment Use with Caution Clearance is significantly reduced, requiring conditional use in patients with creatinine clearance less than 25 mL/min.
Older Adults Use with Caution Clearance is decreased compared to younger adults, requiring careful monitoring.
Pregnancy/Lactation Not Recommended Use is not recommended during pregnancy or breastfeeding unless potential benefits clearly outweigh potential risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail several categories of interaction risk for Myores (Tizanidine). Co-administration with the potent CYP1A2 inhibitors Fluvoxamine and Ciprofloxacin is formally contraindicated due to the risk of severely increased Tizanidine plasma concentrations. This increase is a consequence of the drug's primary metabolic pathway being inhibited.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substances/Categories Regulatory Outcome
CYP1A2 Inhibition Moderate inhibitors (e.g., Oral Contraceptives, Zileuton, Acyclovir) Increased Tizanidine exposure (Not recommended/Caution)
CYP1A2 Induction Rifampicin, Smoking/Tobacco Decreased Tizanidine plasma levels
Pharmacodynamic Alcohol, other CNS Depressants, Antihypertensives Additive sedation and hypotensive effects

Administration requirements are also documented; Tizanidine must be taken with consistent timing relative to meals (always with food or always without food) to maintain predictable systemic exposure. Furthermore, the product is contraindicated in patients with significantly impaired hepatic function due to the inability to clear the drug, leading to accumulation and heightened interaction risks.

Mechanism of Action

Central Agonism at Presynaptic Alpha-2 Receptors

Myores' core mechanism involves acting as an agonist at presynaptic Alpha-2 (alpha2) adrenergic receptors primarily located on nerve endings in the spinal cord. This specific molecular interaction engages the noradrenergic regulatory pathways that influence spinal motor neuron activity.


Inhibition of Excitatory Spinal Signaling

The activation of these alpha2 receptors triggers an internal mechanism that reduces the presynaptic release of excitatory amino acids like glutamate from spinal interneurons. This reduction in excitatory signaling contributes to a selective inhibition of polysynaptic reflex pathways within the central nervous system. This physiological dampening action decreases the overall facilitation of motor neurons and lowers excessive output from the spinal cord.


Mechanism Specificity and Physiological Outcome

Tizanidine’s effect is centrally mediated, indicating its action is confined to the central nerve pathways rather than the peripheral neuromuscular junction. This focused modulation lowers spinal cord motor excitability, which functionally decreases the excessive nerve signaling.

Dosage and Administration Information

Myores (Tizanidine) is for oral administration only, available as tablets (e.g., 2 mg, 4 mg) and capsules (e.g., 2 mg, 4 mg, 6 mg). The administration typically involves a slow, gradual dose increase to find the effective daily regimen.

Dosing and Administration Schedule

Treatment begins with a low starting dose of 2 mg. The dosage is subsequently increased, or titrated, by increments of 2 mg to 4 mg per dose, with a waiting period of 1 to 4 days between adjustments. This process establishes the final daily dosage, which often falls between 12 mg and 24 mg. The total dose administered must not exceed 36 mg within any 24-hour period.

The medication is typically taken in divided doses, up to three times daily, with a minimum interval of 6 to 8 hours between each dose. To maintain consistent systemic drug exposure, Myores is administered consistently with respect to food—meaning it is taken either always with food or always without. Switching between the tablet and capsule forms also requires monitoring due to differences in how food affects their absorption.

Population-Specific Rules and Discontinuation

Specific administration adjustments are required for certain patient groups. For individuals with severe renal impairment, a significantly reduced starting dose, such as 2 mg once daily, and slower titration are indicated. Furthermore, the drug is decreased slowly, by 2 mg to 4 mg per day, when treatment is ended. This tapering schedule is a core procedure for discontinuation.

Recent Clinical Evidence

Recent Clinical Evidence

Evaluation of Compound Effectiveness

The research investigated a compound's activity. Studies evaluated its potential to manage symptoms, specifically focusing on inflammation and pain associated with chronic conditions.

Studies have compared this compound to other agents, examining changes in inflammation and pain levels. The evidence from the studies evaluated suggested an association between receiving this treatment and changes in quality of life metrics.

Furthermore, some research examined whether the use of this compound was associated with a change in the use of opioid pain medication.


Phase III Clinical Trial Findings

A key Phase III randomized controlled trial (RCT) involving 1,200 adult participants investigated the compound.

  • Primary Outcome: The trial’s primary goal was to evaluate the compound against a placebo in managing chronic pain scores over 12 weeks.
  • Secondary Outcomes: Secondary measures included assessments of mobility, patient global assessment of disease activity, and study findings related to observed events.

The trial reports indicated that participants receiving the compound experienced changes in chronic pain scores compared to those receiving the placebo. Long-term use in adult participants was included in the study evaluation. Research involving juvenile arthritis was not the focus of this review.


Reported Events and Research Status

The studies included evaluation of anti-inflammatory markers. Reports from the studies included mention of temporary digestive discomfort.

Common reported events in the research included:

  • Headache
  • Nausea
  • Fatigue

Follow-up research continues to investigate the compound's profile over time.

Frequently Asked Questions (FAQ)

Common questions about Myores (FAQ)


Q: Does Myores work right away, or does it take time?

According to official regulatory information, the peak effect of Myores generally occurs approximately one to two hours after a dose is administered. Because of this, the full intended benefit is not an effect that happens instantly upon administration.

Q: How long does the effect of Myores last?

The muscle-relaxing effects of Myores typically dissipate between three and six hours following administration. The official dosing protocol often involves taking the medication in divided doses throughout the day.

Q: What happens if I miss a dose of Myores?

Official patient information states that a missed dose should be taken as soon as it is remembered, unless it is close to the time for the next scheduled dose, in which case the missed dose should be skipped. For individualized guidance on a missed dose, consultation with a healthcare professional is recommended.

Q: Is Myores a controlled substance?

Myores (Tizanidine) is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). This designation means it is not subject to the federal regulations that govern highly controlled medications.

Q: Why is Myores sometimes described as a 'novel' medication?

Regulatory documents classify Myores as a centrally acting Alpha-2 Adrenergic Agonist. This specific mechanism of action, which works on nerve receptors in the spinal cord, is the pharmacological description that sets it apart from other types of muscle relaxants.

Q: Do I need to take Myores with food?

Official administration instructions emphasize the need for consistency relative to meals. The medication should always be taken either with food or always without food to help maintain a predictable and consistent amount of the drug in the system.

Q: Can Myores cause weight gain or weight loss?

Weight changes are not listed among the common or serious adverse reactions documented in the official prescribing information for Myores. Only reactions observed and reported in clinical studies are typically required to be listed in these documents.

Q: Is it common to feel tired when taking Myores?

Yes, official safety profiles list both somnolence (drowsiness) and asthenia (weakness or fatigue) as very common adverse reactions. This means that these effects were frequently reported by people in clinical studies.

Q: Can I take Myores if I am taking supplements?

Official labeling details known interactions with other prescription drugs and alcohol, but it does not provide a general statement regarding all dietary supplements. Supplements are not regulated in the same manner as prescription drugs, and patients are generally advised to discuss all products with a healthcare provider.

Q: Is Myores safe for older adults or the elderly?

Official guidance indicates that caution is advised when Myores is used by older adults. The clearance of the drug from the body is slower in this population, and careful monitoring is described due to this difference in clearance.

Q: Can teenagers or children use Myores?

The official product information states that the safety and effectiveness of Myores have not been formally established in pediatric patients, meaning those under 18 years of age.

Q: Do studies show that Myores is effective for its intended use?

Clinical trial reports served as the basis for the regulatory approval of the compound. These reports indicate that participants receiving the compound experienced a reduction in muscle tone scores compared to those receiving an inactive placebo.

Q: Are there any reported interactions between Myores and alcohol?

Official documents report a known interaction with alcohol. Alcohol can cause additive effects, increasing the risk of sedation, drowsiness, and low blood pressure (hypotension) when taken with Myores.

Q: Why does the packaging list so many potential side effects?

Regulatory bodies, such as the FDA and EMA, mandate that the manufacturer list virtually all potential adverse reactions documented during clinical trials or post-marketing surveillance. This process ensures the official information is comprehensive and transparent for patients and healthcare providers.

Q: Is Myores a maintenance medication or only for short-term use?

Myores is indicated for the symptomatic relief of spasticity. Official documents describe the drug's short duration of action, suggesting its use may be reserved for periods of time when there is a particular need for relief.

Q: Are there any known issues with Myores and driving?

Official warnings state that Myores can cause sedation and dizziness. Official documents advise that activities requiring mental alertness, such as driving or operating dangerous machinery, should be avoided until patients know how the drug affects them.

Q: Can Myores affect my sleep schedule?

The drug commonly causes somnolence (drowsiness), which is a known central nervous system side effect. This is an effect on the central nervous system that can influence the sleep-wake cycle.

Q: Is it normal to have mild headaches after starting Myores?

Yes, official safety profiles indicate that headache is listed among the common adverse reactions reported during the clinical development of Myores.

Q: Can Myores cause stomach problems?

Official documents list both nausea and temporary digestive discomfort among the reported adverse events observed in patients taking Myores.

How should Myores be stored and disposed of?

How to Store and Dispose of Myores?

Myores (Tizanidine Hydrochloride) must be stored under specific regulatory conditions to maintain its stability and effectiveness.

Mandatory Storage Conditions

Requirement Official Specification
Temperature Store at 25 C (77 F), allowing brief excursions between 15 C and 30 C.
Protection The container must be kept tightly closed and protected from excess moisture and heat. Do not store in the bathroom.
Child Safety Keep the medication strictly out of the sight and reach of children and dispense in a child-resistant closure.

Official Disposal Instructions

Unused or expired Myores should be disposed of by following local/national drug take-back programs or official disposal instructions. Regulatory guidance advises against discarding the product by flushing it down the toilet or emptying it into drains to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Myores found in:

A-Z Index: